Share This Author
Dose Mapping After Endoradiotherapy with 177Lu-DOTATATE/DOTATOC by a Single Measurement After 4 Days
- H. Hänscheid, C. Lapa, A. Buck, M. Lassmann, R. Werner
- MedicineThe Journal of Nuclear Medicine
- 1 January 2018
A single quantitative measurement of the abdominal activity concentration by SPECT/CT 4 d after the administration of 177Lu-DOTATATE/DOTatOC provides a 3-dimensional dose map and can be used to estimate the doses actually absorbed in the treatment cycle with minor additional resources and effort.
Pre-therapy Somatostatin Receptor-Based Heterogeneity Predicts Overall Survival in Pancreatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radionuclide Therapy
In contrast to conventional PET parameters, assessment of intratumoral heterogeneity demonstrated superior prognostic performance in pNET patients undergoing PRRT, and might be useful for patient risk stratification.
Stroke‐induced chronic systolic dysfunction driven by sympathetic overactivity
Although it is established that ischemic stroke is associated with cardiac arrhythmias, myocardial damage, elevated cardiac enzymes, and plasma catecholamines in the acute phase, nothing is known about the delayed consequences of isChemic stroke on cardiovascular function.
68Gallium- and 90Yttrium-/177Lutetium: “theranostic twins” for diagnosis and treatment of NETs
- R. Werner, C. Bluemel, M. Allen-Auerbach, T. Higuchi, K. Herrmann
- MedicineAnnals of Nuclear Medicine
- 20 August 2014
The “theranostic approach” of SSTR-targeting compounds is discussed including an overview of its role for diagnosis, staging and restaging, discussing its way to being established in clinical routine, and giving an outlook about further potentially relevant developments.
Imaging of myocardial inflammation with somatostatin receptor based PET/CT - A comparison to cardiac MRI.
Imaging of Chemokine Receptor 4 Expression in Neuroendocrine Tumors - a Triple Tracer Comparative Approach
The feasibility of non-invasive CXCR4 positron emission tomography/computed tomography (PET/CT) imaging in GEP-NET patients using [68Ga]Pentixafor PET/CT might serve as non- invasive read-out for evaluating the possibility of CX CR4-directed endoradiotherapy in advanced dedifferentiated SSTR-negative tumors.
Survival prediction in patients undergoing radionuclide therapy based on intratumoral somatostatin-receptor heterogeneity
Imaging-based heterogeneity assessment provides prognostic information in PRRT candidates and outperformed conventional PET parameters and can pave the way for individualized patient management.
Predictive Value of 18F-FDG PET in Patients with Advanced Medullary Thyroid Carcinoma Treated with Vandetanib
Pretherapeutic 18F-FDG PET/CT provides prognostic information in patients with advanced MTC scheduled for treatment with the TKI vandetanib, and a low tumor metabolism with an SUVmean of less than 4.0 before treatment predicts a longer PFS.
Prognostic value of positron emission tomography-assessed tumor heterogeneity in patients with thyroid cancer undergoing treatment with radiopeptide therapy.
Prognostic Value of Serum Tumor Markers in Medullary Thyroid Cancer Patients Undergoing Vandetanib Treatment
Whereas tumor marker fluctuations in MTC patients undergoing TKI treatment are a frequent phenomenon, a significant rise in CTN ≥40% turns out to as an early indicator of tumor progression.